Millennium Management
SYRE icon

Millennium Management’s Spyre Therapeutics SYRE Stock Holding History

Millennium Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,528
Closed -$181K – 7478
2021
Q4 		$181K Buy
+1,528
New +$241K ﹤0.01% 5981

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Millennium Management's SYRE Position: Q1 2026 in Review

Millennium Management increased its Spyre Therapeutics (SYRE) stake by 92% in Q1 2026, buying an estimated $2.66M and bringing the position to 146,639 shares worth $7.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2501.

Millennium Management first reported a position in SYRE in Q2 2016 and has held it in 29 quarters since. The position peaked at $12.1M in Q1 2024. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Millennium Management held 146,639 shares of Spyre Therapeutics worth $7.4M as of Q1 2026.
  • Millennium Management bought 70,445 Spyre Therapeutics shares in Q1 2026, an estimated $2.66M.
  • Spyre Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2501 holding.
  • Millennium Management first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 29 quarters since.
  • Millennium Management's Spyre Therapeutics position peaked at $12.1M in Q1 2024.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.